Novo Nordisk A/S, which faces higher demand for its diabetes and weight-loss drugs than it can meet, signed a long-term agreement with Ypsomed Holding AG for the supply of auto-injectors. Ypsomed is ...

(Reuters) -Swiss medical technology company Ypsomed announced on Wednesday a long-term supply deal with Novo Nordisk for autoinjectors, the latest sign of how the Danish drugmaker's weight-loss drug ...

- Supply agreement supports Viridian’s development of potential first- and best-in-class subcutaneous therapies for treatment of thyroid eye disease (TED) - - Ypsomed brings strong track record of ...

Novo Nordisk has spent the last two years scrambling to keep up with skyrocketing demand for its blockbuster GLP-1 drugs, the obesity-focused Wegovy and Type 2 diabetes med Ozempic, forcing it to ...